God these persons are depressing, get a survivor in there, they are giving up before they even start.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=66577#.UJleV9cvnAw
Decision Resources, one of the world’s leading research and advisory
firms for pharmaceutical and healthcare issues, finds that, in light of
repeated clinical trial failures of investigational treatments,
neurologists remain skeptical about the launch potential of
pharmacotherapies in clinical-stage development for the acute or
post-acute treatment of ischemic stroke. As a result, Decision Resources
expects that the market for ischemic stroke therapies will continue to
be a graveyard for new product development in the United States, France,
Germany, Italy, Spain, the United Kingdom and Japan.
According to the Pharmacor advisory service entitled Acute
Ischemic Stroke, interviewed neurologists continue to express
uncertainty about the probability of success for Lundbeck’s thrombolytic
desmoteplase—currently the only novel drug in Phase III development—in
its redesigned pivotal clinical trial program. Although Decision
Resources does not currently forecast approval of desmoteplase, its
approval for use within three-to-nine hours post-stroke onset could
represent one of the most important therapeutic achievements in stroke
in more than a decade, while expanding the proportion of ischemic stroke
patients with access to acute therapy.
The findings also reveal that most interviewed experts convey limited
optimism that neuroprotectants will prove effective in the treatment of
ischemic stroke, given countless failures among such agents in clinical
trials—including the recent discontinuation of D-Pharm’s DP-b99.
Instead, interviewed neurologists agree that new directions in
neurorestorative therapy to aid in post-stroke recovery offer
much-needed avenues for treatment. Although success in this arena is far
from certain, numerous companies are investigating novel approaches to
stimulate neuroplasticity using growth factors, such as Stem Cell
Therapeutics’ NTx-265, or innovative technologies such as PhotoThera’s
NeuroThera Laser System. Meanwhile, developers including Aldagen,
ReNeuron, SanBio/Teijin and Stemedica have initiated the first human
clinical trials of ground-breaking cell-based treatments.
Given the high rate of pipeline attrition in this market, investigators
also remain focused on improving the utility of recombinant tissue
plasminogen activator (rt-PA; alteplase [Genentech’s Activase,
Boehringer Ingelheim’s Actilyse, Kyowa Hakko Kirin’s Activacin,
Mitsubishi Tanabe Pharma’s Grtpa]), the current standard of care in
acute ischemic stroke, through new research, including the use of
advanced imaging to expand the treatment window beyond the
currently-accepted 4.5 hours. Meanwhile, novel reperfusion strategies
such as Cerevast’s ClotBust ER Sonolysis Headframe System, CoAxia’s
NeuroFlo and BrainsGate’s Ischemic Stroke System, offer unique
non-pharmacological approaches alongside currently-approved
neurothrombectomy devices from companies like Concentric Medical,
Penumbra and ev3.
“In recognition of the significant and untapped commercial potential in
this arena, a broad and diverse array of innovative treatment strategies
is in development for the treatment of ischemic stroke, despite myriad
development hurdles,” said Decision Resources Therapeutic Area Director
Bethany Kiernan, Ph.D. “However, in the projected absence of new drug
launches, growth in drug sales and drug-treatment rates in the acute
ischemic stroke market will occur primarily as a result of the gradually
increasing use of rt-PA, aided by a modestly expanded treatment window,
continued improvements in the delivery of stroke care and rising stroke
incidence.”
About Decision Resources
Decision Resources (www.decisionresources.com)
is a world leader in market research publications, advisory services and
consulting designed to help clients shape strategy, allocate resources
and master their chosen markets. Decision Resources is a Decision
Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that
offers best-in-class, high-value information and insights on important
sectors of the healthcare industry. Clients rely on this analysis and
data to make informed decisions. Please visit Decision Resources Group
at www.DecisionResourcesGroup.com.
No comments:
Post a Comment